Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia

被引：0
作者：
Diebold, Kendall [1 ]
Bourne, Garrett [2 ]
Espinoza-Gutarra, Manuel [1 ]
Al-Kadhimi, Zaid [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
Jamy, Omer [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA
来源：
LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 11期
关键词：
DAUNORUBICIN; CHEMOTHERAPY; AML;
D O I：
10.1080/10428194.2024.2373324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1737 / 1739
页数：3
相关论文
共 8 条
  • [1] A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
    Burnett, Alan K.
    Russell, Nigel H.
    Hills, Robert K.
    Kell, Jonathan
    Cavenagh, Jamie
    Kjeldsen, Lars
    McMullin, Mary-Frances
    Cahalin, Paul
    Dennis, Mike
    Friis, Lone
    Thomas, Ian F.
    Milligan, Don
    Clark, Richard E.
    [J]. BLOOD, 2015, 125 (25) : 3878 - 3885
  • [2] Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
    Lee, Je-Hwan
    Kim, Hawk
    Joo, Young-Don
    Lee, Won-Sik
    Bae, Sung Hwa
    Zang, Dae Young
    Kwon, Jihyun
    Kim, Min Kyoung
    Lee, Junglim
    Lee, Gyeong Won
    Lee, Jung-Hee
    Choi, Yunsuk
    Kim, Dae-Young
    Hur, Eun-Hye
    Lim, Sung-Nam
    Lee, Sang-Min
    Ryoo, Hun Mo
    Kim, Hyo Jung
    Hyun, Myung Soo
    Lee, Kyoo-Hyung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2754 - +
  • [3] Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
    Lee, Julia S.
    Wagner, Charlotte B.
    Prelewicz, Stacy
    Kurish, Heena P.
    Walchack, Robert
    Cenin, Danielle A.
    Patel, Seema
    Lo, Mimi
    Schlafer, Danielle
    Li, Belinda K. T.
    Harvey III, R. Donald
    Wasef, Bestis
    Ying, Jian
    Kovacsovics, Tibor
    [J]. REVISTA CHILENA DE LITERATURA, 2023, (108): : 3460 - 3463
  • [4] Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
    Luger, Selina M.
    Sun, Zhuoxin
    Loghavi, Sanam
    Lazarus, Hillard M.
    Rowe, Jacob M.
    Tallman, Martin S.
    Pratz, Keith W.
    Litzow, Mark
    [J]. BLOOD, 2019, 134
  • [5] Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
    Roellig, Christoph
    Steffen, Bjoern
    Schliemann, Christoph
    Mikesch, Jan-Henrik
    Alakel, Nael
    Herbst, Regina
    Haenel, Mathias
    Noppeney, Richard
    Hanoun, Maher
    Kaufmann, Martin
    Racil, Zdenek
    Schaefer-Eckart, Kerstin
    Sauer, Tim
    Neubauer, Andreas
    Baldus, Claudia D.
    Mertova, Jolana
    Jost, Edgar
    Niemann, Dirk
    Novak, Jan
    Krause, Stefan W.
    Scholl, Sebastian
    Hochhaus, Andreas
    Held, Gerhard
    Szotkowski, Tomas
    Schmid, Christoph
    Rank, Andreas
    Fransecky, Lars
    Kramer, Michael
    Fiebig, Frank
    Haake, Annett
    Stoelzel, Friedrich
    Schetelig, Johannes
    Middeke, Jan Moritz
    Platzbecker, Uwe
    Thiede, Christian
    Mueller-Tidow, Carsten
    Berdel, Wolfgang E.
    Serve, Hubert
    Ehninger, Gerhard
    Mayer, Jiri
    Bornhaeuser, Martin
    [J]. BLOOD, 2022, 140
  • [6] Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
    Sierra, Jorge
    Montesinos, Pau
    Thomas, Xavier
    Griskevicius, Laimonas
    Cluzeau, Thomas
    Caillot, Denis
    Legrand, Ollivier
    Minotti, Clara
    Luppi, Mario
    Farkas, Firas
    Bengoudifa, Bourras-Rezki
    Gilotti, Geralyn
    Hodzic, Sejla
    Rambaldi, Alessandro
    Venditti, Adriano
    [J]. BLOOD ADVANCES, 2023, 7 (21) : 6441 - 6450
  • [7] Sravanti R., 2020, ACUTE LEUKEMIAS, P9
  • [8] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
    Stone, R. M.
    Mandrekar, S. J.
    Sanford, B. L.
    Laumann, K.
    Geyer, S.
    Bloomfield, C. D.
    Thiede, C.
    Prior, T. W.
    Doehner, K.
    Marcucci, G.
    Lo-Coco, F.
    Klisovic, R. B.
    Wei, A.
    Sierra, J.
    Sanz, M. A.
    Brandwein, J. M.
    de Witte, T.
    Niederwieser, D.
    Appelbaum, F. R.
    Medeiros, B. C.
    Tallman, M. S.
    Krauter, J.
    Schlenk, R. F.
    Ganser, A.
    Serve, H.
    Ehninger, G.
    Amadori, S.
    Larson, R. A.
    Doehner, H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05) : 454 - 464
1